Company news

Ligand Pharmaceuticals Incorporated news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ligand Reports Third Quarter 2022 Financial Results

November 6, 2022

Ligand Distribution of OmniAb Complete and Business Combination Closed

October 31, 2022

Ligand Announces Completion of OmniAb Spin-Off

October 31, 2022

Ligand to Report Third Quarter Financial Results on November 7

October 25, 2022

Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

October 25, 2022

Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2022

Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off

October 2, 2022

Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

August 23, 2022

Ligand Reports Second Quarter 2022 Financial Results

August 7, 2022

Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 31, 2022

Ligand to Report Second Quarter Financial Results on August 8

July 21, 2022

Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors

June 28, 2022

Ligand Reports First Quarter 2022 Financial Results

May 3, 2022

Ligand to Report First Quarter Financial Results on May 4

April 18, 2022

Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II

March 22, 2022

Ligand Reports Fourth Quarter and Full Year 2021 Financial Results

February 16, 2022

Ligand to Report Fourth Quarter Financial Results on February 17

February 8, 2022

Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy

December 21, 2021

Ligand and GSK Expand Global Collaboration and License Agreement

December 20, 2021

Ligand Reports Third Quarter 2021 Financial Results

November 8, 2021

Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company

November 8, 2021

Ligand to Report Third Quarter Financial Results on November 9, 2021

October 25, 2021

Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™

October 20, 2021

Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma

August 29, 2021

Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

August 15, 2021

Ligand Reports Second Quarter 2021 Financial Results

July 28, 2021

Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458

July 20, 2021

Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes

July 18, 2021

Ligand to Report Second Quarter Financial Results on July 29, 2021

July 15, 2021

Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors

July 13, 2021

GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement

June 1, 2021

Ligand Reports First Quarter 2021 Financial Results

May 2, 2021

Ligand to Report First Quarter Financial Results on May 3, 2021

April 21, 2021

Ligand Reports Fourth Quarter and Full Year 2020 Financial Results

February 2, 2021

Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

February 1, 2021

Ligand’s Fourth Quarter Financial Results to be Reported February 3rd

January 19, 2021

Ligand Receives Milestone Payment from Merck

January 12, 2021

Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders

December 20, 2020

Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies

November 22, 2020

Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients

November 5, 2020

Ligand Reports Third Quarter 2020 Financial Results

October 29, 2020

Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment

October 22, 2020

Ligand Provides Highlights from Today’s Investor Day Event

October 19, 2020

Ligand’s Third Quarter Financial Results to be Reported October 30th

October 18, 2020

Ligand to Divest Vernalis Research Operations

October 11, 2020

Ligand to Host Virtual Investor Day on October 20th

October 1, 2020

Ligand Completes Acquisition of Pfenex Inc.

September 30, 2020

Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.

September 29, 2020

Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million

September 22, 2020

Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences

September 9, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 44 decks. Every deck is listed under its year.